Efficacy Of PF-05089771 In Treating Postoperative Dental Pain

Pfizer235 enrolled

Overview

The objective of this study is to evaluate the overall pain relief of a single dose of PF-05089771 against placebo following third molar extraction.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

235

Conditions

Postoperative Dental Pain

Interventions

PF-05089771DRUG

A single dose of PF-05089771 1600 mg oral solution administered once to the subject on Day 1 postoperatively

PlaceboOTHER

Placebo tablets for ibuprofen: 2 X 200 mg placebo tablets administered orally once to the subject on Day 1 postoperatively

PF-05089771DRUG

A single dose of PF-05089771 450 mg oral solution administered once to the subject on Day 1 postoperatively

Eligibility

Sex: ALLMin age: 18 YearsMax age: 55 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Oral surgery having removed 2 unilateral third molar teeth. * Pre-dose pain intensity score (100 mm VAS \[VAS\]) of at least 50mm within 5 hours of oral surgery * Pre-dose pain intensity score of moderate or severe within 5 hours of oral surgery Exclusion Criteria: * Presence or known history of any clinically significant hematological, hepatic, renal, endocrine, cardiovascular, neurological, psychiatric, gastrointestinal, pulmonary, allergic (including known drug hypersensitivities or allergies, but excluding untreated asymptomatic seasonal allergy) or any metabolic disorder that may increase risk associated with study participation, investigational drug administration or may interfere with interpretation of study results. * Prior use of any type of analgesic or NSAID within 5-half lives of that drug or less before taking the first dose of study medication, except for anesthesia for the procedure. * Active dental infection at the time of surgery. * Recent (within the previous 12 months) history of chronic analgesic or tranquiliser dependency. * Any significant oral surgery complication at the time of surgery or in the immediate postoperative period, or oral surgery that has lasted more than 30 minutes (time from first incision to last suture placement). Subjects who smoke more than 1 pack (20 cigarettes) per day, more than 3 cigars per day or use smokeless tobacco on a daily basis are excluded from the study.

Locations (3)

Central Texas Oral Surgery Associates

Austin, Texas, United States

Premier Research Group Limited

Austin, Texas, United States

PPD Development, LP

Austin, Texas, United States

Outcomes

Primary Outcomes

Total Pain Relief From 0 to 6 Hours (TOTPAR[6])

TOTPAR(6) was defined as the total area under pain relief (PR) curve through first 6 hours after dosing, calculated using trapezoidal rule. PR was assumed to be 0 at 0 hour. PR assessed on a 5-point categorical scale: 0(none), 1 (a little), 2 (some), 3 (a lot) and 4 (complete), at different time points during study up to 6 hours. Total score range for TOTPAR(6): 0 (worst) to 24 (best), higher value indicated greater degree of PR. Posterior mean, standard deviation were estimated based on analysis of covariance (ANCOVA) model with non-informative priors within outlier robust Bayesian framework.

Time frame: 0 to 6 hours

Secondary Outcomes

Number of Participants With Peak Pain Relief (PPR)

PPR was defined as the highest PR score achieved at any time point during the evaluation period, prior to rescue medication. PR was assessed on a 5-point categorical scale: 0 (none), 1 (a little), 2 (some), 3 (a lot) and 4 (complete).

Time frame: 0 to 24 hours

Pain Relief (PR) Score

PR was assessed on a 5-point categorical scale; 0 (none), 1 (a little), 2 (some), 3 (a lot) and 4 (complete).

Time frame: 15, 30, 45, 60, 90 minutes, 2, 3, 4, 6, 8, 24 hours

Pain Intensity Difference (PID)

PID was calculated as pain intensity at baseline (baseline pain severity score range 2 \[moderate\] to 3 \[severe\]) minus pain intensity at the respective post-baseline visit (pain severity score range 0 \[none\] to 3 \[severe\]). Total possible score range for PID: -1 (worst) to 3 (best).

Time frame: 15, 30, 45, 60, 90 minutes, 2, 3, 4, 6, 8, 24 hours

Summed Pain Intensity Difference (SPID)

SPID: area under the PID effect curve from 0 to 6 hours (SPID\[6\]) and 0 to 24 hours (SPID\[24\]). AUC was calculated using the trapezoidal rule. Total score range: -6 (worst) to 18 (best) for SPID(6), and -24 (worst) to 72 (best) for SPID(24). Higher value of SPID indicated greater degree of pain relief. PID was calculated as pain intensity at baseline minus pain intensity at the respective post-baseline visit. Pain intensity was assessed on a categorical scale ranging from 0 (none), 1 (mild), 2 (moderate) and 3 (severe).

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.

Placebo tablets for ibuprofen: 2 X 200 mg placebo tablets administered orally once to the subject on Day 1 postoperatively

PF-05089771DRUG

A single dose of PF-05089771 150 mg oral solution administered once to the subject on Day 1 postoperatively

PlaceboOTHER

Placebo tablets for ibuprofen: 2 X 200 mg placebo tablets administered orally once to the subject on Day 1 postoperatively

IbuprofenDRUG

2 X 200 mg tablets of ibuprofen administered orally once to the subject on Day 1 postoperatively

PlaceboOTHER

Placebo solution for PF-05089771: A single dose of Placebo solution administered once to the subject on Day 1 postoperatively

PlaceboOTHER

Placebo solution for PF-05089771:A single dose of Placebo solution administered once to the subject on Day 1 postoperatively

PlaceboOTHER

Placebo tablets for Ibuprofen: 2 X 200 mg placebo tablets administered orally once to the subject on Day 1 postoperatively

Time frame: 0 to 6 hours; 0 to 24 hours

Total Pain Relief From 0 to 24 Hours (TOTPAR[24])

TOTPAR(24) was defined as the total area under the PR curve through the first 24 hours after dosing, calculated using trapezoidal rule. PR was assumed to be 0 at 0 hour. PR assessed on a 5-point categorical scale: 0 (none), 1 (a little), 2 (some), 3 (a lot) and 4 (complete), at different time points during the study up to 6 hours. Total score range for TOTPAR (24): 0 (worst) to 96 (best), higher value indicated greater degree of PR. The least square mean and standard error are based on ANCOVA model with treatment as a fixed effect and baseline pain intensity as a covariate

Time frame: 0 to 24 hours

Time to Onset of First Perceptible Pain Relief

Participants evaluated the time to first perceptible pain relief by stopping a stopwatch labeled 'first perceptible pain relief' at the moment they first began to experience any relief.

Time frame: 0 to 24 hours

Time to Onset of Meaningful Pain Relief

Participants evaluated the time to first meaningful relief by stopping a stopwatch labeled 'meaningful pain relief' at the moment they first began to experience meaningful relief.

Time frame: 0 to 24 hours

Time to First Use of Rescue Medication

Time to first use of rescue medication (acetaminophen 500 mg or hydrocodone 5 mg) was calculated by subtracting time of first administration of study medication from the rescue medication administration time.

Time frame: 0 to 24 hours

Number of Participants With Global Evaluation of Study Medication

Participant rated the study medication at 6 hours, 24 hours and immediately prior to rescue medication intake (only for participants who took rescue medication\[RM\]), on 5-point categorical scale: 1=poor, 2=fair, 3=good, 4=very good, and 5=excellent.

Time frame: 6, 24 hours, prior to rescue medication (assessed up to 24 hours)

Number of Participants With Study Medication Satisfaction

Participants provided assessment regarding satisfaction with study medication (SM) for pain relief (PR) and overall performance (OP) on a 5-point categorical scale, 1=very dissatisfied (VD), 2=somewhat dissatisfied (SD), 3=neither satisfied nor dissatisfied (NSND), 4=somewhat satisfied (SS) and 5=very satisfied (VS).

Time frame: 6, 24 hours, prior to rescue medication (assessed up to 24 hours)

Plasma PF-05089771 Concentration

Time frame: 0 (pre-dose), 0.5, 1, 2, 4, 6, 8, 10, 24 hours post-dose

Plasma Ibuprofen Concentration

Ibuprofen concentration was reported separately for 2 isomers of ibuprofen: (S)-Ibuprofen, and (R)-Ibuprofen, where S implied sinister (clockwise configuration) and R implied rectus (anti-clockwise configuration).

Time frame: 0 (pre-dose), 0.5, 1, 2, 4, 6, 8, 10, 24 hours post-dose

Number of Participants With Treatment-Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs)

An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between administration of study drug and up to 28 days that were absent before treatment or that worsened relative to pretreatment state.

Time frame: Baseline up to Day 28 (follow-up)

Number of Participants With Clinically Significant Laboratory Findings

Hematology (hemoglobin, hematocrit, red blood cell count, platelets, leukocytes, total neutrophils, eosinophils, basophils, lymphocytes, monocytes), blood chemistry (total bilirubin, direct bilirubin, indirect bilirubin, aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase, creatinine, blood urea nitrogen, fasting glucose, uric acid, sodium, potassium, chloride, bicarbonate, calcium, albumin, total protein, creatine kinase), and urinalysis (urine white blood cells, urine red blood cells) were performed.

Time frame: Baseline up to Day 7 to 10 (follow-up)

Number of Participants With Clinically Significant Vital Signs

Clinically significant vital signs: supine/sitting pulse rate (PR) less than (\<) 40 or more than (\>) 120 beats per minute (bpm), standing PR \<40 or \>140 bpm; systolic blood pressure (BP) \>=30 millimeters of mercury (mmHg) change from baseline; absolute systolic BP \<90 mmHg; diastolic BP \>=20 mmHg change from baseline; absolute systolic BP \<50 mmHg.

Time frame: Baseline up to Day 7 to 10 (follow-up)

Number of Participants With Clinically Significant Electrocardiogram (ECG) Abnormalities

Clinically significant ECG abnormalities: PR interval \>=300 milliseconds (msec); 25% increase from baseline in PR interval when baseline PR was \>200 msec; an increase from baseline of \>=50% in PR interval when baseline PR was \<=200 msec; QRS interval \>=140 msec; an increase from baseline of \>=50% in QRS interval; corrected QT interval (QTc) \>=500 msec.

Time frame: Baseline up to Day 7 to 10 (follow-up)